ClinicalTrials.gg
CompletedNCT00806819Updated Feb 2, 2017Results posted

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

A Phase 3 interventional study of Nintedanib (BIBF1120) and Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed at 167 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-02.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
718
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 19
718 · median 16
Started
2008
with 1 other
Phase 3
3 of 19
none open now
Registered
2nd of 19
by date
Lead sponsor
10 of 19
Boehringer Ingelheim

Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 2 that started in 2008, is one of 3 in phase 3, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient aged 18 years or older.
  2. or cytologically confirmed Stage IIIB, IV (according to AJCC) or recurrent non small cell lung cancer (NSCLC) (non squamous histologies)
  3. Relapse or failure of one chemotherapy (in the case of recurrent disease one additional prior regimen is allowed for adjuvant, or neoadjuvant plus adjuvant therapy).
  4. At least one target tumor lesion that has not been irradiated within the past three months and that can accurately be measured by magnetic resonance imaging (MRI) or computed tomography (CT) in at least one dimension (longest diameter to be recorded) as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral CT.
  5. of at least three months.
  6. (ECOG) score of 0 or 1.
  7. Patient has given written which must be consistent with the International Conference on Harmonization, Good Clinical Practice (ICH-GCP) and local legislation.

Exclusion criteria

Exclusion criteria:

  1. Previous therapy with other vascular endothelial growth factor (VEGF) inhibitors (other than bevacizumab) or pemetrexed for treatment of NSCLC
  2. Treatment with other drugs or treatment in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial
  3. Chemotherapy, hormone therapy, immunotherapy with monoclonal antibodies, treatment with tyrosine kinase inhibitors, or radiotherapy (except for treatment of extremities) within the past four weeks prior to treatment with the trial drug, i.e., the minimum time elapsed since the last anticancer therapy and the first administration of BIBF 1120 must be four weeks
  4. Inability to stop intake of NSAIDS (non steroidal anti inflammatory drugs) for several days
  5. Active (e.g. stable for \<4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants). Dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomisation)
  6. Radiographic evidence of cavitary or necrotic tumors
  7. Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels
  8. History of haemoptysis within the past 3 months
  9. Therapeutic anticoagulation
  10. History of major thrombotic or clinically relevant major bleeding event in the past 6 months
  11. Significant cardiovascular diseases (i.e., hypertension not controlled by medical therapy, unstable angina, history of myocardial infarction within the past 6 months,
  12. Inadequate kidney, liver, blood clotting function
  13. Inadequate blood count
  14. Significant weight loss (> 10 %) within the past 6 weeks prior to treatment in the present trial
  15. Current peripheral neuropathy greater than or equal to (CTCAE) Grade 2 except due to trauma
  16. Pre-existing ascites (abdominal fluid collection) and/or clinically significant pleural effusion ( fluid collection between the lung and chest wall)
  17. Major injuries and/or surgery within the past ten days prior to start of study drug
  18. Incomplete wound healing
  19. Active or chronic and/or B infection Additional exclusion criteria apply
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
718 participants (actual)

Study arms

  • Experimental
    nintedanib (BIBF1120) plus pemetrexed

    nintedanib (BIBF1120) along with standard therapy of pemetrexed

    Drug: Nintedanib (BIBF1120) · Drug: B12 · Drug: dexamethasone (or corticosteroid equivalent) · Drug: Folic Acid · Drug: Pemetrexed

  • Placebo comparator
    Placebo plus pemetrexed

    Pemetrexed standard therapy

    Drug: pemetrexed · Drug: dexamethasone (or corticosteroid equivalent) · Drug: B12 · Drug: placebo · Drug: Folic Acid

  • Experimental
    nintedanib (BIBF1120) monotherapy

    nintedanib (BIBF1120) monotherapy only for patients who discontinue pemetrexed

    Drug: Nintedanib (BIBF1120)

  • Active comparator
    pemetrexed monotherapy

    pemetrexed monotherapy only for patients who discontinue nintedanib (BIBF1120) or placebo

    Drug: Pemetrexed · Drug: B12 · Drug: dexamethasone (or corticosteroid equivalent) · Drug: Folic Acid

  • Placebo comparator
    placebo monotherapy

    placebo monotherapy only for patients who discontinue pemetrexed

    Drug: placebo

Interventions

  • starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.

  • 500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.

  • Drugpemetrexed

    500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.

  • DrugB12

    1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed

  • 4 mg PO bid the day before, the day of and the day after each pemetrexed infusion

  • Drugplacebo

    starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.

  • 4 mg PO bid the day before, the day of and the day after each pemetrexed infusion

  • DrugB12

    1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed

  • 400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.

  • DrugB12

    1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed

  • 4 mg PO bid the day before, the day of and the day after each pemetrexed infusion

  • 400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.

  • Drugplacebo

    starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.

  • 400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.

  • starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.

  • 500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as Assessed by Central Independent Review

    Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Progression free survival (PFS) is defined as the duration of time from date of randomisation to date of progression or death (whatever occurs earlier). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until cut-off date 9 July 2012

Secondary outcomes

  1. Overall Survival (Key Secondary Endpoint)

    Overall Survival (OS) defined as the duration from randomisation to death (irrespective of the reason of death). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  2. Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review

    Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  3. Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator

    Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by investigator according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  4. Objective Tumor Response

    Confirmed objective response is defined as confirmed Complete Response (CR) and Partial Response (PR) and evaluated according to the modified RECIST criteria version 1.0. This endpoint was analysed based on the central independent reviewer as well as the investigator

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  5. Duration of Confirmed Objective Tumour Response

    The duration of objective response is the time from first documented (CR) or (PR) to the time of progression or death and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  6. Time to Confirmed Objective Tumour Response

    Time to confirmed objective response is defined as time from randomisation to the date of first documented (CR) or (PR) and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  7. Disease Control

    Disease control was defined as a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and evaluated according to the modified RECIST criteria version 1.0. This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  8. Duration of Disease Control

    The duration of disease control was defined as the time from randomisation to the date of disease progression or death (which ever occurs first) for patients with disease control. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  9. Change From Baseline in Tumour Size

    Percentage change from baseline in tumour size is defined as decrease in the sum of the longest diameter of the target lesion. Presented means are in fact adjusted best means percentage changes generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (adenocarcinoma vs. non-adenocarcinoma), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no) This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  10. Clinical Improvement.

    Clinical improvement was defined as the time from randomisation to deterioration in body weight and/or Eastern Cooperative Oncology group performance score (ECOG PS) whichever occurred first. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  11. Quality of Life (QoL)

    QoL was measured by standardised questionnaires (EQ-5D, EORTC QLQ-C30, EORTC QLQ-LC13). The EORTC QLQ-C30 comprises of 30 questions, using both multi-item scales and single-item measures. EORTC LC-13 comprises of 13 questions incorporating 1 multi-item scale and a series of single items. The following were the main points of interest: Time to deterioration of cough (QLQ-LC13 question 1), Time to deterioration of dyspnoea (QLQ-LC13, composite of questions 3 to 5), Time to deterioration of pain (QLQ- C30, composite of questions 9 and 19). Time to deterioration of cough, dyspnoea and pain was defined as the time to a 10-point increase from the baseline score. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months

  12. Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide

    Geometric mean of dose normalised predose plasma concentration (Cpre,ss,norm) of nintedanib and of its metabolites BIBF 1202 and BIBF 1202 glucuronide evaluated at steady state based on course 2 and 3. If only one value was available and valid, then this value was used for calculation of Cpre,ss,norm.

    Time frame: Before the administration of nintedanib or placebo and between a window of 30 mins to an hour after administration of trial drug during Course 2 and between 1 and 3 hours after administration of trial drug during Course 3

  13. Incidence and Intensity of Adverse Events

    Incidence and intensity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The worst CTCAE grade per patient is reported and MedDRA version 15.1 used. Serious signs and symptoms of progressive disease were reported as an adverse event in analysis of this endpoint.

    Time frame: From the first drug administration until 28 days after the last drug administration, up to 36 months

07

Results

Posted Nov 20, 2014
Limitations and caveats
Recruitment for the study was stopped early based on the results of a pre defined futility analysis.

Participant flow

Participant flow — Overall Study
MilestoneNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Started353360
Completed72
Not completed346358
Withdrew: Progressive disease (modified recist )217216
Withdrew: Worsening or ae of underlying disease1825
Withdrew: Other ae3840
Withdrew: Protocol violation94
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject3229
Withdrew: Not treated63
Withdrew: Reasons other than stated above2541

Outcome measures

PrimaryProgression Free Survival (PFS) as Assessed by Central Independent Review

Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Progression free survival (PFS) is defined as the duration of time from date of randomisation to date of progression or death (whatever occurs earlier). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until cut-off date 9 July 2012
Reported as:
Median · months
Progression Free Survival (PFS) as Assessed by Central Independent Review
monthsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Progression Free Survival (PFS) as Assessed by Central Independent Review4.4 (2.3 to 9.5)3.6 (1.4 to 7.5)
Statistical analysis
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Cox · p = 0.0435 · Hazard ratio (hr): 0.83 · 95% CI 0.70 to 0.99HR below 1 favors nintedanib
SecondaryOverall Survival (Key Secondary Endpoint)

Overall Survival (OS) defined as the duration from randomisation to death (irrespective of the reason of death). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Median · months
Overall Survival (Key Secondary Endpoint)
monthsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Overall Survival (Key Secondary Endpoint)12.0 (7.0 to 24.2)12.7 (5.4 to 24.0)
Statistical analysis
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Cox · p = 0.8940 · Hazard ratio (hr): 1.01 · 95% CI 0.85 to 1.21HR below 1 favors nintedanib
SecondaryFollow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review

Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Median · Months
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review
MonthsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review4.4 (2.3 to 9.5)3.4 (1.4 to 7.5)
Statistical analysis
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Cox · p = 0.0506 · Hazard ratio (hr): 0.84 · 95% CI 0.70 to 1.00HR below 1 favors nintedanib
SecondaryFollow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator

Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by investigator according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Median · Months
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator
MonthsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator5.3 (2.6 to 9.4)4.3 (1.9 to 8.3)
Statistical analysis
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Cox · p = 0.0865 · Hazard ratio (hr): 0.86 · 95% CI 0.73 to 1.02HR below 1 favors nintedanib
SecondaryObjective Tumor Response

Confirmed objective response is defined as confirmed Complete Response (CR) and Partial Response (PR) and evaluated according to the modified RECIST criteria version 1.0. This endpoint was analysed based on the central independent reviewer as well as the investigator

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Number · % of participants
Objective Tumor Response
% of participantsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Central independent reviewer9.18.3
Investigator assessment15.013.3
Statistical analysis
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Logistic · p = 0.7279 (Odds ratio and p-value are obtained from logistic regression model adjusted for baseline ECOG PS (0 vs 1)) · Odds ratio (or): 1.10 · 95% CI 0.65 to 1.85An odds ratio \>1 indicates a benefit to nintedanib
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Logistic · p = 0.5180 (Odds ratio and p-value are obtained from logistic regression model adjusted for baseline ECOG PS (0 vs 1)) · Odds ratio (or): 1.15 · 95% CI 0.75 to 1.76An odds ratio \>1 indicates a benefit to nintedanib
SecondaryDuration of Confirmed Objective Tumour Response

The duration of objective response is the time from first documented (CR) or (PR) to the time of progression or death and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Median · Months
Duration of Confirmed Objective Tumour Response
MonthsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
central independent reviewer (N=32, 30)6.9 (5.1 to 11.3)4.4 (3.3 to 8.9)
Investigator assessment (N=53, 48)6.5 (4.4 to 12.7)7.2 (4.2 to 16.2)
SecondaryTime to Confirmed Objective Tumour Response

Time to confirmed objective response is defined as time from randomisation to the date of first documented (CR) or (PR) and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Median · Months
Time to Confirmed Objective Tumour Response
MonthsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Central independent review (N=32, 30)2.6 (1.4 to 4.0)2.7 (1.4 to 4.2)
Investigator assessment (N=53, 48)2.6 (1.4 to 3.0)2.8 (1.4 to 3.1)
SecondaryDisease Control

Disease control was defined as a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and evaluated according to the modified RECIST criteria version 1.0. This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Number · % of participants
Disease Control
% of participantsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Central independent review (N=215, 192)60.953.3
Investigator assessment (N=233, 217)66.060.3
Statistical analysis
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Logistic · p = 0.0387 (Odds ratio and p-value are obtained from logistic regression model adjusted for baseline ECOG PS (0 vs 1)) · Odds ratio (or): 1.37 · 95% CI 1.02 to 1.85An odds ratio \>1 indicates a benefit to nintedanib
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Logistic · p = 0.1071 (Odds ratio and p-value are obtained from logistic regression model adjusted for baseline ECOG PS (0 vs 1)) · Odds ratio (or): 1.29 · 95% CI 0.95 to 1.75An odds ratio \>1 indicates a benefit to nintedanib
SecondaryDuration of Disease Control

The duration of disease control was defined as the time from randomisation to the date of disease progression or death (which ever occurs first) for patients with disease control. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Median · Months
Duration of Disease Control
MonthsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Central independent review (N=215, 192)7.4 (4.3 to 11.2)6.8 (4.2 to 12.5)
Investigator assessment (N=233, 217)6.9 (4.4 to 12.5)6.8 (4.4 to 11.1)
SecondaryChange From Baseline in Tumour Size

Percentage change from baseline in tumour size is defined as decrease in the sum of the longest diameter of the target lesion. Presented means are in fact adjusted best means percentage changes generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (adenocarcinoma vs. non-adenocarcinoma), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no) This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Mean · percentage of change in tumor size in mm
Change From Baseline in Tumour Size
percentage of change in tumor size in mmNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Central independent review (N=298, 305)-10.10 (-12.63 to -7.58)-7.53 (-10.03 to -5.04)
Investigator assessment (N=322, 325)-15.60 (-18.75 to -12.46)-11.28 (-14.42 to -8.15)
Statistical analysis
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · ANOVA · p = 0.1558 (P-value generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (adenocarcinoma vs. non-adenocarcinoma), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no))
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · ANOVA · p = 0.0565 (P-value generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (adenocarcinoma vs. non-adenocarcinoma), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no))
SecondaryClinical Improvement.

Clinical improvement was defined as the time from randomisation to deterioration in body weight and/or Eastern Cooperative Oncology group performance score (ECOG PS) whichever occurred first. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Median · Months
Clinical Improvement.
MonthsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Clinical Improvement.7.2 (2.8 to 21.9)7.5 (1.8 to 24.2)
Statistical analysis
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Cox · p = 0.5068 · Hazard ratio (hr): 0.93 · 95% CI 0.74 to 1.16HR below 1 favors nintedanib
SecondaryQuality of Life (QoL)

QoL was measured by standardised questionnaires (EQ-5D, EORTC QLQ-C30, EORTC QLQ-LC13). The EORTC QLQ-C30 comprises of 30 questions, using both multi-item scales and single-item measures. EORTC LC-13 comprises of 13 questions incorporating 1 multi-item scale and a series of single items. The following were the main points of interest: Time to deterioration of cough (QLQ-LC13 question 1), Time to deterioration of dyspnoea (QLQ-LC13, composite of questions 3 to 5), Time to deterioration of pain (QLQ- C30, composite of questions 9 and 19). Time to deterioration of cough, dyspnoea and pain was defined as the time to a 10-point increase from the baseline score. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until data cut-off (15 February 2013), Up to 30 months
Reported as:
Median · Months
Quality of Life (QoL)
MonthsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Time to deterioration of cough6.0 (2.2 to 23.6)4.3 (1.4 to NA)
Time to deterioration of dyspnoea2.4 (0.9 to 6.4)2.0 (0.8 to 5.7)
Time to deterioration of pain2.8 (1.2 to 7.0)2.7 (1.1 to 8.0)
Statistical analysis
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Cox · p = 0.1181 · Hazard ratio (hr): 0.83 · 95% CI 0.66 to 1.05HR below 1 favors nintedanib
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Cox · p = 0.4264 · Hazard ratio (hr): 0.93 · 95% CI 0.77 to 1.12HR below 1 favors nintedanib
  • Nintedanib Plus Pemetrexed vs Placebo Plus Pemetrexed · Regression, Cox · p = 0.8929 · Hazard ratio (hr): 1.01 · 95% CI 0.84 to 1.23HR below 1 favors nintedanib
SecondaryDose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide

Geometric mean of dose normalised predose plasma concentration (Cpre,ss,norm) of nintedanib and of its metabolites BIBF 1202 and BIBF 1202 glucuronide evaluated at steady state based on course 2 and 3. If only one value was available and valid, then this value was used for calculation of Cpre,ss,norm.

Time frame:
Before the administration of nintedanib or placebo and between a window of 30 mins to an hour after administration of trial drug during Course 2 and between 1 and 3 hours after administration of trial drug during Course 3
Reported as:
Geometric mean · ng/mL/mg
Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide
ng/mL/mgNintedanib Plus PemetrexedNintedanib 150 mg Bid Plus Pemetrexed
Nintedanib BIBF 1120 (N=188, 39)0.0883 ± 66.40.103 ± 72.9
Nintedanib BIBF 1202 (N=188, 40)0.131 ± 1230.151 ± 125
Nintedanib BIBF 1202 glucuronide (N=184, 39)1.40 ± 1691.72 ± 185
SecondaryIncidence and Intensity of Adverse Events

Incidence and intensity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The worst CTCAE grade per patient is reported and MedDRA version 15.1 used. Serious signs and symptoms of progressive disease were reported as an adverse event in analysis of this endpoint.

Time frame:
From the first drug administration until 28 days after the last drug administration, up to 36 months
Reported as:
Number · % of participants
Incidence and Intensity of Adverse Events
% of participantsNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
CTCAE grade 14.99.2
CTCAE grade 222.230.5
CTCAE grade 346.134.5
CTCAE grade 412.47.8
CTCAE grade 59.812.0

Adverse events

Collected over From the first drug administration until 28 days after the last drug administration, up to 36 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib Plus Pemetrexed—104/347 (30%)320/347 (92.2%)
Placebo Plus Pemetrexed—117/357 (32.8%)312/357 (87.4%)
Most frequent serious events
Showing 10 of 185
Most frequent serious events
EventNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
PneumoniaInfections and infestations11/34716/357
DyspnoeaRespiratory, thoracic and mediastinal disorders9/34711/357
AnaemiaBlood and lymphatic system disorders5/3478/357
Febrile neutropeniaBlood and lymphatic system disorders7/3473/357
DehydrationMetabolism and nutrition disorders6/3474/357
VomitingGastrointestinal disorders3/3476/357
Respiratory failureRespiratory, thoracic and mediastinal disorders5/3476/357
Pleural effusionRespiratory, thoracic and mediastinal disorders5/3473/357
General physical health deteriorationGeneral disorders4/3473/357
HaemoptysisRespiratory, thoracic and mediastinal disorders4/3471/357
Most frequent other events
Showing 10 of 42
Most frequent other events
EventNintedanib Plus PemetrexedPlacebo Plus Pemetrexed
Alanine aminotransferase increasedInvestigations149/34787/357
Aspartate aminotransferase increasedInvestigations129/34768/357
NauseaGastrointestinal disorders126/347118/357
FatigueGeneral disorders116/347127/357
DiarrhoeaGastrointestinal disorders118/34754/357
Decreased appetiteMetabolism and nutrition disorders97/34789/357
VomitingGastrointestinal disorders84/34768/357
Neutrophil count decreasedInvestigations74/34747/357
DyspnoeaRespiratory, thoracic and mediastinal disorders45/34770/357
ConstipationGastrointestinal disorders50/34765/357

Baseline characteristics

Randomised set uncut (RS): all patients who were randomised whether patients had received study treatment or not. Patients were allocated to the treatment groups as randomised, regardless of the actual medication taken.

Age, Continuous
Age, Continuous(years)Nintedanib Plus PemetrexedPlacebo Plus PemetrexedTotal
Mean59.2 ± 10.358.7 ± 10.959.0 ± 10.6
Gender
Gender(Participants)Nintedanib Plus PemetrexedPlacebo Plus PemetrexedTotal
Female158152310
Male195208403
08

Study locations

167 sites
  • Boehringer Ingelheim Investigational Site
    Downy, California, United States
  • Boehringer Ingelheim Investigational Site
    Fountain Valley, California, United States
  • Boehringer Ingelheim Investigational Site
    Fullerton, California, United States
  • Boehringer Ingelheim Investigational Site
    Long Beach, California, United States
  • Boehringer Ingelheim Investigational Site
    Meriden, Connecticut, United States
  • Boehringer Ingelheim Investigational Site
    Aventura, Florida, United States
  • Boehringer Ingelheim Investigational Site
    Boynton Beach, Florida, United States
  • Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • Boehringer Ingelheim Investigational Site
    New Port Richey, Florida, United States
  • Boehringer Ingelheim Investigational Site
    Port St. Lucie, Florida, United States
  • Boehringer Ingelheim Investigational Site
    Stuart, Florida, United States
  • Boehringer Ingelheim Investigational Site
    Galesburg, Illinois, United States
  • Boehringer Ingelheim Investigational Site
    Skokie, Illinois, United States
  • Boehringer Ingelheim Investigational Site
    Indianapolis, Indiana, United States
  • Boehringer Ingelheim Investigational Site
    New Albany, Indiana, United States
  • Boehringer Ingelheim Investigational Site
    Witchita, Kansas, United States
  • Boehringer Ingelheim Investigational Site
    Ashland, Kentucky, United States
  • Boehringer Ingelheim Investigational Site
    Louisville, Kentucky, United States
  • Boehringer Ingelheim Investigational Site
    Burlington, Massachusetts, United States
  • Boehringer Ingelheim Investigational Site
    Springfield, Massachusetts, United States
  • Boehringer Ingelheim Investigational Site
    St. Louis park, Minnesota, United States
  • Boehringer Ingelheim Investigational Site
    Grand Island, Nebraska, United States
  • Boehringer Ingelheim Investigational Site
    Farmington, New Mexico, United States
  • Boehringer Ingelheim Investigational Site
    Dunkirk, New York, United States
  • Boehringer Ingelheim Investigational Site
    Goshen, New York, United States
  • Boehringer Ingelheim Investigational Site
    Lake Success, New York, United States
  • Boehringer Ingelheim Investigational Site
    Nyack, New York, United States
  • Boehringer Ingelheim Investigational Site
    Asheville, North Carolina, United States
  • Boehringer Ingelheim Investigational Site
    Canton, Ohio, United States
  • Boehringer Ingelheim Investigational Site
    Sandusky, Ohio, United States
  • Boehringer Ingelheim Investigational Site
    Ephrata, Pennsylvania, United States
  • Boehringer Ingelheim Investigational Site
    Langhorne, Pennsylvania, United States
  • Boehringer Ingelheim Investigational Site
    Philadelphia, Pennsylvania, United States
  • Boehringer Ingelheim Investigational Site
    Germantown, Tennessee, United States
  • Boehringer Ingelheim Investigational Site
    Amarillo, Texas, United States
  • Boehringer Ingelheim Investigational Site
    Seattle, Washington, United States
  • Boehringer Ingelheim Investigational Site
    Spokane, Washington, United States
  • Boehringer Ingelheim Investigational Site
    Madison, Wisconsin, United States
  • Boehringer Ingelheim Investigational Site
    Milwaukee, Wisconsin, United States
  • Boehringer Ingelheim Investigational Site
    Bs. As. Codigo Buenos Aires, Argentina
  • Boehringer Ingelheim Investigational Site
    Córdoba, Argentina
  • Boehringer Ingelheim Investigational Site
    Pergamino, Argentina
  • Boehringer Ingelheim Investigational Site
    Quilmes Buenos Aires, Argentina
  • Boehringer Ingelheim Investigational Site
    Rosario, Santa Fe, Argentina
  • Boehringer Ingelheim Investigational Site
    San Miguel de Tucuman, Argentina
  • Boehringer Ingelheim Investigational Site
    San Miguel de Tucumán, Argentina
  • Boehringer Ingelheim Investigational Site
    Sydney, New South Wales, Australia
  • Boehringer Ingelheim Investigational Site
    Brisbane, Queensland, Australia
  • Boehringer Ingelheim Investigational Site
    Adelaide, South Australia, Australia
  • Boehringer Ingelheim Investigational Site
    Toorak Gardens, South Australia, Australia
  • Boehringer Ingelheim Investigational Site
    Melbourne, Victoria, Australia
  • Boehringer Ingelheim Investigational Site
    Perth, Western Australia, Australia
  • Boehringer Ingelheim Investigational Site
    Sydney, Australia
  • Boehringer Ingelheim Investigational Site
    Banja Luka, Bosnia and Herzegovina
  • Boehringer Ingelheim Investigational Site
    Sarajevo, Bosnia and Herzegovina
  • Boehringer Ingelheim Investigational Site
    Belo Horizonte,Minas Gerais, Brazil
  • Boehringer Ingelheim Investigational Site
    Belo Horizonte, Brazil
  • Boehringer Ingelheim Investigational Site
    Cachoeira do Itapemirim-ES, Brazil
  • Boehringer Ingelheim Investigational Site
    Campinas SP, Brazil
  • Boehringer Ingelheim Investigational Site
    Caxias do Sul, Brazil
  • Boehringer Ingelheim Investigational Site
    Curitiba, Brazil
  • Boehringer Ingelheim Investigational Site
    Florianopolis, Brazil
  • Boehringer Ingelheim Investigational Site
    Goiania Goias, Brazil
  • Boehringer Ingelheim Investigational Site
    Ijui, Brazil
  • Boehringer Ingelheim Investigational Site
    Itajai, Brazil
  • Boehringer Ingelheim Investigational Site
    Jau/SP, Brazil
  • Boehringer Ingelheim Investigational Site
    Londrina, Parana, Brazil
  • Boehringer Ingelheim Investigational Site
    Pelotas Rio Grande do Sul, Brazil
  • Boehringer Ingelheim Investigational Site
    Porto Alegre, Brazil
  • Boehringer Ingelheim Investigational Site
    Rio de Janeiro, Brazil
  • Boehringer Ingelheim Investigational Site
    Salvador Bahia, Brazil
  • Boehringer Ingelheim Investigational Site
    Santo Andre, Sao Paulo, Brazil
  • Boehringer Ingelheim Investigational Site
    Santo Andre, Brazil
  • Boehringer Ingelheim Investigational Site
    Sao Paulo - SP, Brazil
  • Boehringer Ingelheim Investigational Site
    Sao Paulo, Brazil
  • Boehringer Ingelheim Investigational Site
    Sorocaba Sao Paulo, Brazil
  • Boehringer Ingelheim Investigational Site
    Thunder Bay, Ontario, Canada
  • Boehringer Ingelheim Investigational Site
    Toronto, Ontario, Canada
  • Boehringer Ingelheim Investigational Site
    Montreal, Quebec, Canada
  • Boehringer Ingelheim Investigational Site
    Quebec, Canada
  • Boehringer Ingelheim Investigational Site
    Jardin del Mar, Renaca, Chile
  • Boehringer Ingelheim Investigational Site
    Las Condes, Chile
  • Boehringer Ingelheim Investigational Site
    Santiago, Chile
  • Boehringer Ingelheim Investigational Site
    Temuco, Chile
  • Boehringer Ingelheim Investigational Site
    Monteria, Cordoba, Colombia
  • Boehringer Ingelheim Investigational Site
    Cuenca, Ecuador
  • Boehringer Ingelheim Investigational Site
    Quito, Ecuador
  • Boehringer Ingelheim Investigational Site
    Augsburg, Germany
  • Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • Boehringer Ingelheim Investigational Site
    Gauting, Germany
  • Boehringer Ingelheim Investigational Site
    Halle (Saale), Germany
  • Boehringer Ingelheim Investigational Site
    Hemer, Germany
  • Boehringer Ingelheim Investigational Site
    München, Germany
  • Boehringer Ingelheim Investigational Site
    Hong Kong, Hong Kong
  • Boehringer Ingelheim Investigational Site
    Deszk, Hungary
  • Boehringer Ingelheim Investigational Site
    Nyíregyháza, Hungary
  • Boehringer Ingelheim Investigational Site
    Pécs, Hungary
  • Boehringer Ingelheim Investigational Site
    Dublin 8, Ireland
  • Boehringer Ingelheim Investigational Site
    Daegu, Korea, Republic of

Showing the first 100 of 167 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lesaffre E, Edelman MJ, Hanna NH, Park K, Thatcher N, Willemsen S, Gaschler-Markefski B, Kaiser R, Manegold C. Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial. Ann Oncol. 2017 Jul 1;28(7):1419-1426. doi: 10.1093/annonc/mdx042. PubMed 28184431 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Jun 2011 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2008
First posted
Dec 11, 2008
Start
Dec 2008
Primary completionActual
Jun 2011
CompletionActual
Dec 2015
Results first posted
Nov 20, 2014
Last update
Feb 2, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00806819
Responsible party
Sponsor
First posted
Dec 11, 2008
Start date
Dec 2008
Primary completion
Jun 2011
Completion
Dec 2015
Results posted
Nov 20, 2014
Last update
Feb 2, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · B12

Start the discussion